SERIOUS CELLULITIS IN A PATIENT WITH ATOPIC DERMATITIS TREATED WITH BARICITINIB: A CASE REPORT (submitted in 2019)
5PSQ-062
EFFECTIVENESS OF ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE AND INFLUENCE OF RESPONSE TO FIRSTLINE TREATMENT (submitted in 2019)
5PSQ-061
ALEMTUZUMAB FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS: EFFECTIVENESS AND SAFETY (submitted in 2019)
5PSQ-060
EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN CLINICAL PRACTICE FOR CROHN'S DISEASE (submitted in 2019)
5PSQ-059
PHARMACIST-LED OBSERVATIONAL STUDY ON QUALITY OF LIFE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: EVIDENCES FROM THE QOSMOS STUDY (submitted in 2019)
5PSQ-058
THE IMPORTANCE OF MONITORING ADVERSE DRUG REACTIONS: DATA FROM THE TREATMENT OF A RARE DISEASE (submitted in 2019)
5PSQ-057
ANALYSIS OF INCIDENCE OF HEPATOTOXICITY ASSOCIATED WITH THE USE OF TOCILIZUMAB (submitted in 2019)
5PSQ-056
EXPERIENCE WITH TOFACINITIB AND BARICITINIB IN RHEUMATOID ARTHRITIS (submitted in 2019)
5PSQ-055
FILGRASTIM IN EARLY STAGE BREAST CANCER: DIFFERENCES BETWEEN TWO SMALL HOSPITALS (submitted in 2019)
5PSQ-054
EXAMINATION OF A NEW METHOD FOR ANALYSING IDENTITY AND CONCENTRATION OF DRUGS IN READY TO USE PREPARATIONS: PROOF OF CONCEPTS OF THE DRUGLOG SYSTEM (submitted in 2019)
5PSQ-053
OFF-LABEL USE OF RITUXIMAB IN SYSTEMIC AUTOIMMUNE DISEASES (submitted in 2019)
5PSQ-052
EARLY RESULTS FROM THE EFFECTIVENESS AND SAFETY EVALUATION OF BIOSIMILAR RITUXIMAB AND BRAND-RITUXIMAB IN GLOMERULAR INFLAMMATORY DISEASE (submitted in 2019)
5PSQ-051
IMMUNE RELATED ADVERSE EVENTS IN CANCER PATIENTS TREATED WITH CONTROL POINT INHIBITORS (submitted in 2019)
5PSQ-050
SUCCESSFUL DESENSITISATION IN A PATIENT WITH DASATINIB HYPERSENSITIVITY (submitted in 2019)
5PSQ-049
PALBOCICLIB IN METASTATIC BREAST CANCER TREATMENT: REAL LIFE TOXICITY AND FREQUENCY OF DOSE REDUCTION OR PERMANENT DISCONTINUATION. (submitted in 2019)
